Rhia Ventures
VC Fund
San Francisco, United States
Rhia Ventures is a VC fund in San Francisco focused on Health Care and Biotechnology. Rhia Ventures invests in reproductive healthcare solutions that empower women.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 14%
- Fund size:
- $38M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Rhia Ventures invests in
Stages Rhia Ventures invests in
Countries Rhia Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.3M–$8.3M
- Series A
- $5M–$15M
Investment Focus
Industry
- Health Care 11 (79%)
- Biotechnology 5 (36%)
- Medical 3 (21%)
- Women's 3 (21%)
- Wellness 2 (14%)
Stage
- Seed 6 (43%)
- Series A 5 (36%)
- Pre-Seed 1 (7%)
- Venture - Series Unknown 1 (7%)
Country
- United States 8 (57%)
- Canada 1 (7%)
- Israel 1 (7%)
- Denmark 1 (7%)
- Switzerland 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Elizabeth Bailey
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
Jeff Kaplan
Limited Partner Advisory Committee
|
Limited Partner Advisory Committee | Total investments: 0 | Find email | |
Stasia Obremskey
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Eli empowers women to understand their body and the transitions it goes through every day, and across life. We develop a device that uses saliva to capture hormone fluctuations at home, and an app that gives women the information they want to own their health decisions. | $3.6M / Seed / Apr 04, 2023 | ||
| Twentyeight Health is building a digital healthcare home for underserved women, providing telemedicine, medication delivery, and care coordination. Twentyeight Health is revolutionizing access to high-quality, inclusive women's health services for Medicaid recipients. | $8.3M / Seed / Feb 13, 2023 | ||
| Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible. | $7.2M / Series A / Nov 10, 2022 | ||
| AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that willimprove clinical practice and help reduce patient mortality. | $5M / Seed / Sep 13, 2022 | ||
| YourChoice Therapeutics develops a non-hormonal contraceptive product. Its technology is based on the “molecular condom” concept: the active compound inhibits vigorous sperm motility and prevents sperm from fertilizing the egg. | $15M / Series A / Jul 20, 2022 | ||
| Cayaba Care is a maternal health company offering community-based clinical services via technology-enabled multidisciplinary care teams. | $12M / Series A / May 19, 2022 | ||
| The mission of the Fogarty Institute for Innovation is to promote medical innovation by providing support to promising innovators and researchers as they transform their creative ideas into practical solutions to improve patient care. They offer mentorship and education at every step of the process, coordinating access to intellectual, physical,and financial resources to propel medical concepts from initiation to application. | $5M / Series A / Nov 02, 2021 | ||
| Raydiant Oximetry is a medical device company focused on improving outcomes for mothers and babies during childbirth. The company develops a low-cost, non-invasive biomedical device to monitor the oxygen levels in fetal blood. It develops and distributes a non-invasive technology that directly monitors a babies' oxygenation during pregnancy.This technology will lead to better patient care and greatly reduce the number of unnecessary cesarean sections.Founded in 2015 by Neil Ray, Raydiant Oximetry is headquartered in Mountain View, California. | $5M / Series A / Nov 01, 2021 | ||
| Testmate Health is a medtech startup and award-winning spin-off of University of Geneva (Switzerland). We have developed a smartphone compatible platform test kit that diagnoses any disease with an identifiable DNA or RNA sequence - without the need for a lab, providing results directly at home in minutes. Based on this platform, our firstsolution is the first rapid urine self-test for the four most common sexually transmitted diseases (STD). One million new STDs are diagnosed a day, and yet the best improvements to date still need a lab, with results taking up to 7 days to be ready. Our easy to use all-in-one-kit provides results in minutes, anywhere, at any time, and the result is scannable by a smartphone to enable people to immediately gain access to treatment – if needed. Further test-kits with other diseases are in the pipeline to empower users to skip the waiting room, and take charge of their health from home. | $1.9M / Seed / Oct 21, 2021 | ||
| Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible. | $10.7M / Series A / Oct 20, 2021 | ||
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Rhia Ventures invest in?
Rhia Ventures invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Rhia Ventures's check size?
Rhia Ventures typically joins rounds of $1.3M–$8.3M at Seed and $5M–$15M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Rhia Ventures participates in.
How do I contact Rhia Ventures?
Public channels for Rhia Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Rhia Ventures?
The team at Rhia Ventures includes Elizabeth Bailey (Managing Director), Jeff Kaplan (Limited Partner Advisory Committee) and Stasia Obremskey (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
